微信号

功能介绍

Biotechnology

生物技术

In August 2019, the President named the bioeconomy as one of the three R&D priorities for FY2021 under the main priority of American Heath & Bioeconomic Innovation.

2019年8月，总统将生物经济列为2021财年美国健康与生物经济创新的三大研发重点之一。

A key factor in unleashing the full potential of the bioeconomy will be the ability to harness the power of complex biological systems (primarily cells) in a predictable and safe way for the manufacture of advanced therapeutics, sustainable fuels, chemical feedstocks, and advanced materials. 

释放生物经济的全部潜力的一个关键因素将是能够以可预测和安全的方式利用复杂生物系统(主要是细胞)的力量，用于制造先进的治疗方法、可持续燃料、化学原料和先进材料。

Remarkable progress has been made in this field throughout the last decade, particularly with respect to genome read, write, and edit technologies, but there is still a widely recognized need for measurements and standards to enable better predictive engineering, and to support reliable and safe translation of engineered biological systems into products and other use cases.

在过去的十年中，这一领域取得了显著的进展，特别是在基因组读取、写入和编辑技术方面，但是仍然存在广泛认可的测量和标准需求，以实现更好的预测工程，并支持将工程生物系统可靠和安全地转化为产品和其他用例。

To support the U.S. bioeconomy, NIST is building next-generation measurement science (biometrology) capabilities and engineering biology laboratories for accelerating responsible biotechnology innovations. Along with supporting basic technology research and development, NIST helps facilitate the translation of technologies to scale through global standardization efforts and partnerships with industry. As metrology is central and essential to all engineering biology research, NIST also plays a significant role in convening stakeholders to discuss challenges and solutions as the field moves forward. 

为了支持美国的生物经济，NIST正在建设下一代测量科学(生物计量学)能力和工程生物学实验室，以加速负责任的生物技术创新。除了支持基础技术的研究和开发，NIST还帮助促进技术的转化，以便通过全球标准化工作和与行业的合作伙伴关系进行扩展。由于计量学是所有工程生物学研究的核心和关键，随着该领域的发展，NIST在召集利益相关者讨论挑战和解决方案方面也发挥着重要作用。

NIST plays a key role in developing techniques, standards and reference materials used as benchmarks for manufacturing process control and product quality assurance, in order to facilitate commerce for the bioeconomy. The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), the Manufacturing USA institute sponsored by NIST with the University of Delaware, and its participants benefit directly from this work. Recent highlights of NIST work in this field include:

NIST在开发技术、标准和参考材料方面发挥着关键作用，这些标准和参考材料被用作制造过程控制和产品质量保证的基准，以促进生物经济的商业发展。国家生物制药制造创新研究所(NIIMBL)，由NIST和特拉华大学赞助的美国制造研究所，及其参与者直接受益于这项工作。

NIST在该领域的最新工作亮点包括:

• The launch of the NIST Living Measurement Systems Foundry to advance U.S. synthetic and engineering biology efforts. The foundry enables the engineering of cells for reliable and safe use in dynamic and unpredictable environments for applications such as living therapeutics, environmental sensing, and structured materials fabrication. An automated facility for high throughput testing and measuring of engineering microbes, the foundry provides a mechanism for partnership with other organizations developing measurement approaches.

• 启动NIST生活测量系统铸造厂，以推进美国合成和工程生物学的努力。该代工使细胞工程能够在动态和不可预测的环境中可靠和安全地使用，用于生命治疗、环境传感和结构材料制造等应用。作为工程微生物高通量测试和测量的自动化设备，铸造厂提供了与其他开发测量方法的组织合作的机制。
  

• The production of world-leading measurements, standards, technologies, and data needed to drive advances in biosciences and biotechnology.

• 生产世界领先的测量、标准、技术和数据，以推动生物科学和生物技术的进步。
  

• The NIST Genome in a Bottle Consortium brings together over 100 industry and academic partners to develop reference standards, methods, and data to enable the translation of whole human genome sequencing to clinical practice. NIST human genome reference standards have helped the Food and Drug Administration approval of diagnostics, provided confidence to enable rapid response of global health issues, accelerated the development of next-gen measurement capabilities, and provided high confidence data underpinning global biological research related to sequencing.

• NIST瓶中基因组联盟汇集了100多个行业和学术合作伙伴，共同开发参考标准、方法和数据，使全人类基因组测序能够转化为临床实践。NIST的人类基因组参考标准帮助美国食品和药物管理局批准了诊断方法，为快速应对全球健康问题提供了信心，加速了下一代测量能力的发展，并为与测序相关的全球生物研究提供了高可信度的数据。
  

• The NIST Gene Editing Consortium brings together 32 leading industry, academic, and government partners to identify pre-competitive standards and measurements to meet the needs of the gene-editing field. NIST leads the Measurement Working Group of this consortium and our researchers are actively developing new capabilities for assessing genome editing outcomes based on the inputs of this group. Working with its partners, NIST recently released a list of lexicons as a unified standard set of terms and definitions serving the needs of the genome editing community. This will provide critical support to various scientific and policy discussions.

• NIST基因编辑联盟汇集了32个领先的行业、学术和政府合作伙伴，以确定竞争前的标准和测量方法，以满足基因编辑领域的需求。NIST领导着该联盟的测量工作组，我们的研究人员正在积极开发新的能力，以评估基于该小组投入的基因组编辑结果。NIST与其合作伙伴合作，最近发布了一份词典列表，作为一套统一的标准术语和定义，服务于基因组编辑社区的需求。这将为各种科学和政策讨论提供关键支持。
  

• NIST is assisting the growing regenerative medicine industry to meet their measurement assurance and other challenges. NIST has been working with companies and other federal agencies to develop measurement assurance strategies for quantitative measurement of living systems needed for translation and commercialization of advanced therapies, including cell therapy, gene therapy, and tissue engineered products.

• NIST正在协助不断增长的再生医学行业，以满足他们的测量保证和其他挑战。NIST一直在与公司和其他联邦机构合作，为先进疗法(包括细胞疗法、基因疗法和组织工程产品)的转化和商业化所需的生命系统的定量测量制定测量保证策略。
  

• NIST is developing key microbiome measurements needed to accelerate the availability of microbiome diagnostics and to enable manufacturing of microbiome therapeutics. Researchers are also developing measurements and standards for pathogen detection in biodefense and infectious disease diagnostics.

• NIST正在开发关键的微生物组测量，以加速微生物组诊断的可用性，并使微生物组治疗药物的制造成为可能。研究人员还在开发生物防御和传染病诊断中病原体检测的测量方法和标准。
  

With increased support NIST can continue to provide the necessary measurement and standards capabilities and infrastructure that will be required to unlock the full potential of the U.S. bioeconomy.

随着支持的增加，NIST可以继续提供必要的测量和标准能力和基础设施，这将需要释放美国生物经济的全部潜力。

扫一扫

微信号

功能介绍

Biotechnology

生物技术

In August 2019, the President named the bioeconomy as one of the three R&D priorities for FY2021 under the main priority of American Heath & Bioeconomic Innovation.

2019年8月，总统将生物经济列为2021财年美国健康与生物经济创新的三大研发重点之一。

A key factor in unleashing the full potential of the bioeconomy will be the ability to harness the power of complex biological systems (primarily cells) in a predictable and safe way for the manufacture of advanced therapeutics, sustainable fuels, chemical feedstocks, and advanced materials. 

释放生物经济的全部潜力的一个关键因素将是能够以可预测和安全的方式利用复杂生物系统(主要是细胞)的力量，用于制造先进的治疗方法、可持续燃料、化学原料和先进材料。

Remarkable progress has been made in this field throughout the last decade, particularly with respect to genome read, write, and edit technologies, but there is still a widely recognized need for measurements and standards to enable better predictive engineering, and to support reliable and safe translation of engineered biological systems into products and other use cases.

在过去的十年中，这一领域取得了显著的进展，特别是在基因组读取、写入和编辑技术方面，但是仍然存在广泛认可的测量和标准需求，以实现更好的预测工程，并支持将工程生物系统可靠和安全地转化为产品和其他用例。

To support the U.S. bioeconomy, NIST is building next-generation measurement science (biometrology) capabilities and engineering biology laboratories for accelerating responsible biotechnology innovations. Along with supporting basic technology research and development, NIST helps facilitate the translation of technologies to scale through global standardization efforts and partnerships with industry. As metrology is central and essential to all engineering biology research, NIST also plays a significant role in convening stakeholders to discuss challenges and solutions as the field moves forward. 

为了支持美国的生物经济，NIST正在建设下一代测量科学(生物计量学)能力和工程生物学实验室，以加速负责任的生物技术创新。除了支持基础技术的研究和开发，NIST还帮助促进技术的转化，以便通过全球标准化工作和与行业的合作伙伴关系进行扩展。由于计量学是所有工程生物学研究的核心和关键，随着该领域的发展，NIST在召集利益相关者讨论挑战和解决方案方面也发挥着重要作用。

NIST plays a key role in developing techniques, standards and reference materials used as benchmarks for manufacturing process control and product quality assurance, in order to facilitate commerce for the bioeconomy. The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), the Manufacturing USA institute sponsored by NIST with the University of Delaware, and its participants benefit directly from this work. Recent highlights of NIST work in this field include:

NIST在开发技术、标准和参考材料方面发挥着关键作用，这些标准和参考材料被用作制造过程控制和产品质量保证的基准，以促进生物经济的商业发展。国家生物制药制造创新研究所(NIIMBL)，由NIST和特拉华大学赞助的美国制造研究所，及其参与者直接受益于这项工作。

NIST在该领域的最新工作亮点包括:

• The launch of the NIST Living Measurement Systems Foundry to advance U.S. synthetic and engineering biology efforts. The foundry enables the engineering of cells for reliable and safe use in dynamic and unpredictable environments for applications such as living therapeutics, environmental sensing, and structured materials fabrication. An automated facility for high throughput testing and measuring of engineering microbes, the foundry provides a mechanism for partnership with other organizations developing measurement approaches.

• 启动NIST生活测量系统铸造厂，以推进美国合成和工程生物学的努力。该代工使细胞工程能够在动态和不可预测的环境中可靠和安全地使用，用于生命治疗、环境传感和结构材料制造等应用。作为工程微生物高通量测试和测量的自动化设备，铸造厂提供了与其他开发测量方法的组织合作的机制。
  

• The production of world-leading measurements, standards, technologies, and data needed to drive advances in biosciences and biotechnology.

• 生产世界领先的测量、标准、技术和数据，以推动生物科学和生物技术的进步。
  

• The NIST Genome in a Bottle Consortium brings together over 100 industry and academic partners to develop reference standards, methods, and data to enable the translation of whole human genome sequencing to clinical practice. NIST human genome reference standards have helped the Food and Drug Administration approval of diagnostics, provided confidence to enable rapid response of global health issues, accelerated the development of next-gen measurement capabilities, and provided high confidence data underpinning global biological research related to sequencing.

• NIST瓶中基因组联盟汇集了100多个行业和学术合作伙伴，共同开发参考标准、方法和数据，使全人类基因组测序能够转化为临床实践。NIST的人类基因组参考标准帮助美国食品和药物管理局批准了诊断方法，为快速应对全球健康问题提供了信心，加速了下一代测量能力的发展，并为与测序相关的全球生物研究提供了高可信度的数据。
  

• The NIST Gene Editing Consortium brings together 32 leading industry, academic, and government partners to identify pre-competitive standards and measurements to meet the needs of the gene-editing field. NIST leads the Measurement Working Group of this consortium and our researchers are actively developing new capabilities for assessing genome editing outcomes based on the inputs of this group. Working with its partners, NIST recently released a list of lexicons as a unified standard set of terms and definitions serving the needs of the genome editing community. This will provide critical support to various scientific and policy discussions.

• NIST基因编辑联盟汇集了32个领先的行业、学术和政府合作伙伴，以确定竞争前的标准和测量方法，以满足基因编辑领域的需求。NIST领导着该联盟的测量工作组，我们的研究人员正在积极开发新的能力，以评估基于该小组投入的基因组编辑结果。NIST与其合作伙伴合作，最近发布了一份词典列表，作为一套统一的标准术语和定义，服务于基因组编辑社区的需求。这将为各种科学和政策讨论提供关键支持。
  

• NIST is assisting the growing regenerative medicine industry to meet their measurement assurance and other challenges. NIST has been working with companies and other federal agencies to develop measurement assurance strategies for quantitative measurement of living systems needed for translation and commercialization of advanced therapies, including cell therapy, gene therapy, and tissue engineered products.

• NIST正在协助不断增长的再生医学行业，以满足他们的测量保证和其他挑战。NIST一直在与公司和其他联邦机构合作，为先进疗法(包括细胞疗法、基因疗法和组织工程产品)的转化和商业化所需的生命系统的定量测量制定测量保证策略。
  

• NIST is developing key microbiome measurements needed to accelerate the availability of microbiome diagnostics and to enable manufacturing of microbiome therapeutics. Researchers are also developing measurements and standards for pathogen detection in biodefense and infectious disease diagnostics.

• NIST正在开发关键的微生物组测量，以加速微生物组诊断的可用性，并使微生物组治疗药物的制造成为可能。研究人员还在开发生物防御和传染病诊断中病原体检测的测量方法和标准。
  

With increased support NIST can continue to provide the necessary measurement and standards capabilities and infrastructure that will be required to unlock the full potential of the U.S. bioeconomy.

随着支持的增加，NIST可以继续提供必要的测量和标准能力和基础设施，这将需要释放美国生物经济的全部潜力。

扫一扫